New brain cancer wafer shows promise in recurrent glioblastoma trial
NCT ID NCT07349693
First seen Feb 01, 2026 · Last updated May 25, 2026 · Updated 17 times
Summary
This study tests a new treatment called Cerebraca Wafer for people with recurrent glioblastoma, a serious brain cancer. The wafer is placed in the brain during surgery and is followed by standard chemotherapy. The goal is to see if it helps patients live longer and controls the disease better than chemotherapy alone. About 175 adults with first or second recurrence of glioblastoma will take part.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT GLIOBLASTOMA, IDH-WILDTYPE are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Legorreta Cancer Center Warren Alpert Medical School of Brown University
Providence, Rhode Island, 02903, United States
Contact Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.